Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent Merdad Parsey, who is preparing to leave early next year.

Q2 2025 Management View CEO Nello Mainolfi outlined major progress in 2025, declaring “the updates we've shared in the first ...

Kymera Therapeutics Inc (KYMR) extends cash runway into 2028, bolstered by key partnerships with Gilead and Sanofi, despite ...

Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new insulin manufacturing facility in Beijing, reflecting increasing demand for ...

August 16, 2025 10:25 am - Industry revenue for Necitumumab is estimated to rise to $1249.4 million by 2035 from $612.2 million of 2024. The revenue ...

Kymera Therapeutics may have signed a $750 million deal with Gilead, but the Watertown biotech also suffered a setback in its partnership with Sanofi and announced a $250 million secondary offering.

Gilead Sciences named former Sanofi executive Dietmar Berger as chief medical officer, effective Jan. 2, succeeding Merdad Parsey. Berger had held the same role at Sanofi, where he was also global ...

Nurix Therapeutics Reports Positive Clinical Data for Bexobrutideg and Advances Collaborations with Sanofi and Gilead, Highlighting Financial Growth July 09, 2025 — 04:14 pm EDT ...

Consequently, Sanofi has decided to let go of KT-474, which was being evaluated for the treatment of hidradenitis suppurativa (HS) and atopic dermatitis (AD) in two phase IIb dose-ranging studies.

These assets are backed by partnerships with Gilead (GILD) and Sanofi (SNY). Thus, I still feel it’s justified to be bullish on the stock despite its inherent biotech risks. Oncology Degraders ...